[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442.
[2] Kawakita D, Matsuo K. Alcohol and head and neck cancer. Cancer Metastasis Rev. 2017 Sep;36(3):425-434. doi: 10.1007/s10555-017-9690-0.
[3] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210.
[4] Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011 Jan;11(1):9-22. doi: 10.1038/nrc2982.
[5] Liu C, Yu Z, Huang S, Zhao Q, Sun Z, Fletcher C, Jiang Y, Zhang D. Combined identification of three miRNAs in serum as effective diagnostic biomarkers for HNSCC. EBioMedicine. 2019 Dec;50:135-143. doi: 10.1016/j.ebiom.2019.11.016.
[6] Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0.
[7] Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, Moros EG, Harrison LB. The future of personalised radiotherapy for head and neck cancer. Lancet Oncol. 2017 May;18(5):e266-e273. doi: 10.1016/S1470-2045(17)30252-8.
[8] Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol. 2015 Oct 10;33(29):3293-304. doi: 10.1200/JCO.2015.61.1509.
[9] Huang SH, O'Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017 Jul;18(7):40. doi: 10.1007/s11864-017-0484-y.
[10] Haughey BH, Sinha P, Kallogjeri D, Goldberg RL, Lewis JS Jr, Piccirillo JF, Jackson RS, Moore EJ, Brandwein-Gensler M, Magnuson SJ, et al. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral Oncol. 2016 Nov;62:11-19. doi: 10.1016/j.oraloncology.2016.09.004.
[11] Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A,et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130.
[12] Qi Z, Barrett T, Parikh AS, Tirosh I, Puram SV. Single-cell sequencing and its applications in head and neck cancer. Oral Oncol. 2019 Dec;99:104441. doi: 10.1016/j.oraloncology.2019.104441.
[13] Bunbanjerdsuk S, Vorasan N, Saethang T, Pongrujikorn T, Pangpunyakulchai D, Mongkonsiri N, Arsa L, Thokanit N, Pongsapich W, Anekpuritanang T, et al. Oncoproteomic and gene expression analyses identify prognostic biomarkers for second primary malignancy in patients with head and neck squamous cell carcinoma. Mod Pathol. 2019 Jul;32(7):943-956. doi: 10.1038/s41379-019-0211-2.
[14] Jin Z, Zhao X, Cui L, Xu X, Zhao Y, Younai F, Messadi D, Hu S. UBE2C promotes the progression of head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 2020 Mar 5;523(2):389-397. doi: 10.1016/j.bbrc.2019.12.064.
[15] Shen Y, Liu J, Zhang L, Dong S, Zhang J, Liu Y, Zhou H, Dong W. Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets. Biomed Res Int. 2019 Aug 7;2019:7376034. doi: 10.1155/2019/7376034.
[16] Wintergerst L, Selmansberger M, Maihoefer C, Schüttrumpf L, Walch A, Wilke C, Pitea A, Woischke C, Baumeister P, Kirchner T, et al. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC). Mol Oncol. 2018 Dec;12(12):2085-2101. doi: 10.1002/1878-0261.12388.
[17] Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004 Apr 29;350(18):1828-37. doi: 10.1056/NEJMoa032520.
[18] Foy JP, Bazire L, Ortiz-Cuaran S, Deneuve S, Kielbassa J, Thomas E, Viari A, Puisieux A, Goudot P, Bertolus C, et al. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Med. 2017 Sep 1;15(1):165. doi: 10.1186/s12916-017-0929-y.
[19] Kostareli E, Holzinger D, Bogatyrova O, Hielscher T, Wichmann G, Keck M, Lahrmann B, Grabe N, Flechtenmacher C, Schmidt CR, et al. HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas. J Clin Invest. 2013 Jun;123(6):2488-501. doi: 10.1172/JCI67010.
[20] Qin Y, Wang J, Zhu G, Li G, Tan H, Chen C, Pi L, She L, Chen X, Wei M, et al. CCL18 promotes the metastasis of squamous cell carcinoma of the head and neck through MTDH-NF-κB signalling pathway. J Cell Mol Med. 2019 Apr;23(4):2689-2701. doi: 10.1111/jcmm.14168.
[21] Yu B, Zhang Y, Wu K, Wang L, Jiang Y, Chen W, Yan M. CD147 promotes progression of head and neck squamous cell carcinoma via NF-kappa B signaling. J Cell Mol Med. 2019 Feb;23(2):954-966. doi: 10.1111/jcmm.13996.
[22] Chen WC, Li QL, Pan Q, Zhang HY, Fu XY, Yao F, Wang JN, Yang AK. Xenotropic and polytropic retrovirus receptor 1 (XPR1) promotes progression of tongue squamous cell carcinoma (TSCC) via activation of NF-κB signaling. J Exp Clin Cancer Res. 2019 Apr 17;38(1):167. doi: 10.1186/s13046-019-1155-6.
[23] Dylawerska A, Barczak W, Wegner A, Golusinski W, Suchorska WM. Association of DNA repair genes polymorphisms and mutations with increased risk of head and neck cancer: a review. Med Oncol. 2017 Nov 15;34(12):197. doi: 10.1007/s12032-017-1057-4.
[24] Das R, Kundu S, Laskar S, Choudhury Y, Ghosh SK. Assessment of DNA repair susceptibility genes identified by whole exome sequencing in head and neck cancer. DNA Repair (Amst). 2018 Jun-Jul;66-67:50-63. doi: 10.1016/j.dnarep.2018.04.005.
[25] Mutlu P, Mutlu M, Yalcin S, Unsoy G, Yaylaci A, Saylam G, Akin I, Korkmaz H, Gunduz U. Detection of XRCC1 gene polymorphisms in Turkish head and neck squamous cell carcinoma patients: a comparative analysis with different populations. J BUON. 2015 Mar-Apr;20(2):540-7.
[26] Gao P, He M, Zhang C, Geng C. Integrated analysis of gene expression signatures associated with colon cancer from three datasets. Gene. 2018 May 15;654:95-102. doi: 10.1016/j.gene.2018.02.007.
[27] Inazu M. Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target for cancer therapy. Biopharm Drug Dispos. 2014 Nov;35(8):431-49. doi: 10.1002/bdd.1892.
[28] Nishiyama R, Nagashima F, Iwao B, Kawai Y, Inoue K, Midori A, Yamanaka T, Uchino H, Inazu M. Identification and functional analysis of choline transporter in tongue cancer: A novel molecular target for tongue cancer therapy. J Pharmacol Sci. 2016 Jun;131(2):101-9. doi: 10.1016/j.jphs.2016.04.022.
[29] Fan YL, Chen L, Wang J, Yao Q, Wan JQ. Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway. FEBS Lett. 2013 Dec 11;587(24):3892-7. doi: 10.1016/j.febslet.2013.09.029.
[30] Banerjee AK, Read CA, Griffiths MH, George PJ, Rabbitts PH. Clonal divergence in lung cancer development is associated with allelic loss on chromosome 4. Genes Chromosomes Cancer. 2007 Sep;46(9):852-60. doi: 10.1002/gcc.20472.
[31] Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C, et al. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res. 2013 Jun;11(6):568-78. doi: 10.1158/1541-7786.MCR-12-0710.
[32] Yan L, Cai K, Liang J, Liu H, Liu Y, Gui J. Interaction between miR-572 and PPP2R2C, and their effects on the proliferation, migration, and invasion of nasopharyngeal carcinoma (NPC) cells. Biochem Cell Biol. 2017 Oct;95(5):578-584. doi: 10.1139/bcb-2016-0237.
[33] Wu AH, Huang YL, Zhang LZ, Tian G, Liao QZ, Chen SL. MiR-572 prompted cell proliferation of human ovarian cancer cells by suppressing PPP2R2C expression. Biomed Pharmacother. 2016 Feb;77:92-7. doi: 10.1016/j.biopha.2015.12.005.
[34] Wang J, Xi X, Shang W, Acharya A, Li S, Savkovic V, Li H, Haak R, Schmidt J, Liu X, et al. The molecular differences between human papillomavirus-positive and -negative oropharyngeal squamous cell carcinoma: A bioinformatics study. Am J Otolaryngol. 2019 Jul-Aug;40(4):547-554. doi: 10.1016/j.amjoto.2019.04.015.